Robuta

https://www.rediff.com/business/report/hc-allows-zydus-to-sell-generic-version-of-cancer-drug-nivolumab/20260113.htm
Delhi High Court has cleared the way for Zydus Lifesciences to proceed with the sale of its version of the cancer drug nivolumab in India. nivolumab is used to...
generic versioncancer drughcallowszydus
https://serio-registry.org/node/66
year oldmale patientnivolumabinducedmulti
https://pubmed.ncbi.nlm.nih.gov/32509368/
Immunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of several malignancies. The purpose of this report is...
small cellinhibitornivolumabassociatedhypereosinophilia
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_medium=email&utm_source=govdelivery
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic
https://www.mayo.edu/research/clinical-trials/cls-20517036
Learn more about services at Mayo Clinic.
studycomparecmpcombinednivolumab
https://www.wikidata.org/wiki/Q51383875
scientific article published in October 2016
large cell lymphomacase reportnivolumabrefractoryanaplastic
https://pubmed.ncbi.nlm.nih.gov/35319641/
Hodgkin's Lymphoma has a very good prognosis. In the unusually refractory patients allogeneic transplantation offers a chance of cure. The so-called checkpoint...
hodgkin diseasetreatmentrelapseallogeneictransplantation
https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-nivolumab-to-treat-a-type-of-cancer-of-the-lymph-system
EAMS scientific opinion given to Nivolumab to treat a type of cancer of the lymph system, including the public assessment report.
access to medicinesscientific opinionwithdrawnearlyscheme
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2014-02674
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
phase iiiiitrialnivolumabipilimumab
https://pubmed.ncbi.nlm.nih.gov/40271863/
ClinicalTrials.gov identifier: NCT04043975; University Hospital Medical Information Network-Clinical Trial Registration: UMIN000036772.
safety profileeffectivenessnivolumabplusipilimumab